yongjun wang
6
1
1
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
17%
1 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Emergency Stroke Unit for Acute Cerebrovascular Events ( ESU-ACE-B )
Role: lead
Affect of Multiple Health Education on Medication Persistence and Clinical Prognosis of Ischemic Stroke Patients
Role: lead
Affect of Health Education on Statins Medication Persistence and ClinicaL Prognosis of Ischemic Stroke Patients (HELP)
Role: lead
Tongxinluo Capsule in Ischemic Stroke Patients(TISS)
Role: lead
China Atrial Fibrillation Screening in Acute Ischemic Stroke Patients
Role: lead
Comparative Effectiveness of Neuroprotectants on Acute Ischemic Stroke
Role: lead
All 6 trials loaded